Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.59 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18342235 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL476886 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| Oxalic Acid SCHEMBL1624804 | 0.97 | SLC6A2 (0.57) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL5143426 | 0.91 | CTSD (0.55) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL1623585 | 0.91 | CTSD (0.55) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL2727813 | 0.91 | CTSD (0.55) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL3811903 | 0.90 | DCUN1D1 (0.58) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL4132155 | 0.90 | SLC6A2 (0.60) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| Hydrochloric Acid SCHEMBL21410210 | 0.89 | DCUN1D1 (0.57) | SLC6A2SLC6A4KCNH2SLC6A3CTSD | |
| SCHEMBL1624807 | 0.87 | SLC6A2 (0.55) | SLC6A2SLC6A4KCNH2SLC6A3CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030557-B1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | IDIENCE CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | disclosed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9682973-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-06-20 | — | — | US | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | disclosed |
| EP-2411010-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111050-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, PARP1 | SLC6A2 4664/4885SLC6A4 4250/4885KCNH2 4100/4885 |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | SLC6A2 1115/4885SLC6A4 2205/4885KCNH2 1706/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | SLC6A2 1100/4885SLC6A4 2190/4885KCNH2 1603/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | SLC6A2 1115/4885SLC6A4 2205/4885KCNH2 1706/4885 |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, NUDT5 | SLC6A2 4431/4885SLC6A4 3692/4885KCNH2 2825/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | SLC6A2 1100/4885SLC6A4 2190/4885KCNH2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.